Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Baxalta Demonstrates Commitment to Innovation in Hemophilia and Blood Disorders at ISTH 2015 Congress
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc. (NYSE:BAX), will highlight the breadth and depth of its hematology portfolio and commitment to innovation in hemophilia and blood disorders with the presentation of new data at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress taking place June 20-25 in Toronto, Canada. Researchers and investigators will discuss the safety and effectiveness of the company’s leading brands ADVATE and FEIBA, and will showcase strong clinical data supporting investigational products, including BAX 855 intended for the treatment of hemophilia A, BAX 111 for von Willebrand disease, and potential new treatments for other coagulation disorders. [ABSTRACT FROM PUBLISHER]
No Comments.